These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 19440239)

  • 21. A single immunization with CoVaccine HT-adjuvanted H5N1 influenza virus vaccine induces protective cellular and humoral immune responses in ferrets.
    Bodewes R; Kreijtz JH; van Amerongen G; Geelhoed-Mieras MM; Verburgh RJ; Heldens JG; Bedwell J; van den Brand JM; Kuiken T; van Baalen CA; Fouchier RA; Osterhaus AD; Rimmelzwaan GF
    J Virol; 2010 Aug; 84(16):7943-52. PubMed ID: 20519384
    [TBL] [Abstract][Full Text] [Related]  

  • 22. H5N1 vaccine-specific B cell responses in ferrets primed with live attenuated seasonal influenza vaccines.
    Cheng X; Eisenbraun M; Xu Q; Zhou H; Kulkarni D; Subbarao K; Kemble G; Jin H
    PLoS One; 2009; 4(2):e4436. PubMed ID: 19209231
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Induction of heterosubtypic cross-protection against influenza by a whole inactivated virus vaccine: the role of viral membrane fusion activity.
    Budimir N; Huckriede A; Meijerhof T; Boon L; Gostick E; Price DA; Wilschut J; de Haan A
    PLoS One; 2012; 7(1):e30898. PubMed ID: 22303469
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Heterosubtypic T-cell responses against avian influenza H5 haemagglutinin are frequently detected in individuals vaccinated against or previously infected with human subtypes of influenza.
    Goy K; Von Bibra S; Lewis J; Laurie K; Barr I; Anderson D; Hellard M; Ffrench R
    Influenza Other Respir Viruses; 2008 Jul; 2(4):115-25. PubMed ID: 19453462
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Protection against H5N1 highly pathogenic avian and pandemic (H1N1) 2009 influenza virus infection in cynomolgus monkeys by an inactivated H5N1 whole particle vaccine.
    Nakayama M; Shichinohe S; Itoh Y; Ishigaki H; Kitano M; Arikata M; Pham VL; Ishida H; Kitagawa N; Okamatsu M; Sakoda Y; Ichikawa T; Tsuchiya H; Nakamura S; Le QM; Ito M; Kawaoka Y; Kida H; Ogasawara K
    PLoS One; 2013; 8(12):e82740. PubMed ID: 24376571
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Tetravaccine--new fundamental approach to prevention of influenza pandemic].
    Onishchenko GG; Zverev VV; Katlinskiĭ AV; Semchenko AV; Korovkin SA; Mel'nikov SIa; Mironov AN
    Zh Mikrobiol Epidemiol Immunobiol; 2007; (4):15-9. PubMed ID: 17882832
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pulmonary surfactant-biomimetic nanoparticles potentiate heterosubtypic influenza immunity.
    Wang J; Li P; Yu Y; Fu Y; Jiang H; Lu M; Sun Z; Jiang S; Lu L; Wu MX
    Science; 2020 Feb; 367(6480):. PubMed ID: 32079747
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cross-Reactive Neuraminidase-Inhibiting Antibodies Elicited by Immunization with Recombinant Neuraminidase Proteins of H5N1 and Pandemic H1N1 Influenza A Viruses.
    Liu WC; Lin CY; Tsou YT; Jan JT; Wu SC
    J Virol; 2015 Jul; 89(14):7224-34. PubMed ID: 25948745
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cytotoxic T cells are the predominant players providing cross-protective immunity induced by {gamma}-irradiated influenza A viruses.
    Furuya Y; Chan J; Regner M; Lobigs M; Koskinen A; Kok T; Manavis J; Li P; Müllbacher A; Alsharifi M
    J Virol; 2010 May; 84(9):4212-21. PubMed ID: 20164231
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The kinase mTOR modulates the antibody response to provide cross-protective immunity to lethal infection with influenza virus.
    Keating R; Hertz T; Wehenkel M; Harris TL; Edwards BA; McClaren JL; Brown SA; Surman S; Wilson ZS; Bradley P; Hurwitz J; Chi H; Doherty PC; Thomas PG; McGargill MA
    Nat Immunol; 2013 Dec; 14(12):1266-76. PubMed ID: 24141387
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Induction of cytotoxic T-lymphocyte and antibody responses against highly pathogenic avian influenza virus infection in mice by inoculation of apathogenic H5N1 influenza virus particles inactivated with formalin.
    Sawai T; Itoh Y; Ozaki H; Isoda N; Okamoto K; Kashima Y; Kawaoka Y; Takeuchi Y; Kida H; Ogasawara K
    Immunology; 2008 Jun; 124(2):155-65. PubMed ID: 18205793
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Memory T cells established by seasonal human influenza A infection cross-react with avian influenza A (H5N1) in healthy individuals.
    Lee LY; Ha do LA; Simmons C; de Jong MD; Chau NV; Schumacher R; Peng YC; McMichael AJ; Farrar JJ; Smith GL; Townsend AR; Askonas BA; Rowland-Jones S; Dong T
    J Clin Invest; 2008 Oct; 118(10):3478-90. PubMed ID: 18802496
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Annual vaccination against influenza virus hampers development of virus-specific CD8⁺ T cell immunity in children.
    Bodewes R; Fraaij PL; Geelhoed-Mieras MM; van Baalen CA; Tiddens HA; van Rossum AM; van der Klis FR; Fouchier RA; Osterhaus AD; Rimmelzwaan GF
    J Virol; 2011 Nov; 85(22):11995-2000. PubMed ID: 21880755
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Protective memory responses are modulated by priming events prior to challenge.
    Rutigliano JA; Morris MY; Yue W; Keating R; Webby RJ; Thomas PG; Doherty PC
    J Virol; 2010 Jan; 84(2):1047-56. PubMed ID: 19889782
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Replication-Defective Influenza Virus Harboring H5 and H7 Hemagglutinins Provides Protection against H5N1 and H7N9 Infection in Mice.
    Tian X; Landreth S; Lu Y; Pandey K; Zhou Y
    J Virol; 2021 Jan; 95(3):. PubMed ID: 33177192
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antibody contributes to heterosubtypic protection against influenza A-induced tachypnea in cotton rats.
    Straight TM; Ottolini MG; Prince GA; Eichelberger MC
    Virol J; 2008 Mar; 5():44. PubMed ID: 18355405
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and immunogenicity of a vero cell culture-derived whole-virus H5N1 influenza vaccine in chronically ill and immunocompromised patients.
    van der Velden MV; Geisberger A; Dvorak T; Portsmouth D; Fritz R; Crowe BA; Herr W; Distler E; Wagner EM; Zeitlinger M; Sauermann R; Stephan C; Ehrlich HJ; Barrett PN; Aichinger G
    Clin Vaccine Immunol; 2014 Jun; 21(6):867-76. PubMed ID: 24739978
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A vaccine prepared from a non-pathogenic H5N1 avian influenza virus strain confers protective immunity against highly pathogenic avian influenza virus infection in cynomolgus macaques.
    Itoh Y; Ozaki H; Tsuchiya H; Okamoto K; Torii R; Sakoda Y; Kawaoka Y; Ogasawara K; Kida H
    Vaccine; 2008 Jan; 26(4):562-72. PubMed ID: 18164788
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antibodies and CD4(+) T-cells mediate cross-protection against H5N1 influenza virus infection in mice after vaccination with a low pathogenic H5N2 strain.
    Droebner K; Haasbach E; Fuchs C; Weinzierl AO; Stevanovic S; Büttner M; Planz O
    Vaccine; 2008 Dec; 26(52):6965-74. PubMed ID: 18848593
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Seasonal influenza vaccine elicits heterosubtypic immunity against H5N1 that can be further boosted by H5N1 vaccination.
    van Maurik A; Sabarth N; Dacho HS; Brühl P; Schwendinger M; Crowe BA; Noel Barrett P; Kistner O; Keith Howard M
    Vaccine; 2010 Feb; 28(7):1778-85. PubMed ID: 20018265
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.